Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MONTHLY OTC STOCKS REBOUND FROM DISMAL FEBRUARY: DART BIGGEST GAINER

Executive Summary

The "F-D-C" Monthly Index of OTC stocks climbed 4.6% during the month of March to 161.0, rebounding from a dismal February when all four Components dropped. The OTC stocks were led by the Pharmaceutical group, which jumped 8.3% to 110.5. Pacing the Pharmaceuticals were Genentech (up 2-1/4 to 36), Paco (ahead 2-1/4 to 18-1/4), Par (ahead 2 to 10-1/4), Zenith (ahead 1-1/4 to 15-3/4) and Glaxo and Viratek, both up 1 to 12 and 11-1/4, respectively. Genentech's gain followed a 4-1/2 plummet in February, as the biotech firm continues to hover in 1984 in the mid-30 range. Enzo added 1/2 to 17-1/4. Other biotech stocks Hybritech (off 2 to 13-1/4) and Biogen (down 1/4 to 12-3/4) slipped among the Diversifieds. Fractional advances turned in by the drug group were Reid-Provident's 7/8 rise to 4, Nelson R&D's 3/4 increase to 13, Lypho-Med's 3/4 surge to 18, Smith Labs' 3/4 climb to 9-7/8, Teva's 1/2 gain to 2-7/8 and Cetus' 3/8 increase to 11-3/8. Largest loser on the Pharmaceutical Component was Mylan, which slipped 3 to 17-3/4. Scherer fell 7/8 to 13 and Immunex, which announced late in the month that human clinical trials were underway at NIH for its interleukin-2 product to be marketed under an agreement with Roche, dropped 1/2 to 6. Solid advances turned in among the Diversifieds by IMS (up 2 to 25-1/4) and Sperti (ahead 1-1/4 to 3-3/8) were just enough to offset Hybritech's loss, ULI's 4-3/4 plunge to 12-1/4, and Natl. Patent's 1-1/4 decline to 21-1/2. Overall, the group was ahead in a slight .1% to 159.2. Beecham added 1/8 to 4-1/2 and Chattem gained 1/2 to 20-3/4. The only OTC Component on the downside was the group of eight drug and medical supply Whslrs. The distributors stumbled .5% to 344.6, as S-P Drug dropped 1-1/4 to 9-3/4, Durr-Fillauer fell 1 to 13-3/4, and Owens, Minor slipped 1/4 to 13-1/4. The biggest advance among the Whslrs. was recorded by Ketchum, which added 1 to 16. Spectro was ahead 5/8 to 17-3/4 and Bindley-Western, FoxMeyer and Synergex were each up 1/2, to 14-1/4, 24-3/4 and 100-1/4, respectively. The Chains, up 6.8% as a group to 311.4, were led by Dart Drug (up 9 to 68) and Pay 'N Save (ahead 1-7/8 to 21-1/8). Dart's jump more than compensates for the stock's 6-point plunge in February. Hook declined 1-1/4 to 21-1/4, Medicine Shoppe was off 3/8 to 17-1/2, and Begley dropped 1/4 to 16.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

ID1131849

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel